Abiopharma

🔍 Gold Kelly (Executive)

Company: Camp4 Therapeutics Corp (CAMP)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Common Stock at $3.96 per share (Direct)
  Date: 2026-08-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: H | shares_owned_after: 76,467.00 | Footnotes: F3

Footnotes:

• F1: The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
• F2: The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
• F3: Includes 2,039 shares previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under Rule 16b-3(c).